|
 |
| 1-4
September, 2006 Pragati Maidan, New Delhi, India |
 |
|
|
India `Pricks` its way into vaccines.
Pharma cos develop products for global market at affordable prices.
Growing at a ‘healthy’ rate of 35%, the spurt in the vaccine market is attributed to the entry of new players and new vaccines. The result of big pharma companies pulling out is that new outfits together with the old hands, is busy exploiting new technologies in the vaccine market.
It was only a matter of time. With the US being one of the largest importers of measles vaccine from India and Pune serum institute being the world’s largest manufacturer of DTP vaccine, domestic pharma majors in India are now developing vaccines for the global market at affordable prices.
Be it Mumbai based Nicholas Piramal who are looking for a collaborative research with foreign educational institutions or Lupin Laboratories also a Mumbai based company who after identifing the new TB molecule is now together with Shantha Biotechnics, looking at manufacturing TB vaccine to combat the disease. The earlier mentioned Pune based Serum Institute has also developed a aerosol measles vaccine under a WHO project.
Improved vaccines are now an everyday happening. It is after a 40-year drought that Indians have discovered faster cure for dreaded diseases like TB.
As an analyst was quoted saying “There has been a massive flight of big drug companies out of vaccines. The growing demand from the developed as well as developing countries, the shrinking base of vaccine manufacturers in the developed countries and cost pressures have all combined to give India a major push to fill up the gap.”
The growing rate of collaboration between Private and public academic and research institutions is also a significant reason that has resulted in the crafting of new vaccines to tackle diseases which have never previously been addressed in India.
Date: 20-Nov-2004
Back
|
|
 |
|
|
|
 |
